



ATTACH TO #13

FORM PTO-1449 (Modified)	Attorney Docket No.: 15280-317100US	Application No.: 09/381,497
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION AND DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: FitzGerald et al.	
	Filing Date: September 20, 1999	Group: 1642

Reference Designation		U.S. PATENT DOCUMENTS				Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)

RECEIVED  
MAY 15 2001  
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
AA	WO94/29350	22 Dec. 1994	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
AB	J. DE KRUIF ET AL.: "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes." FEBS LETTERS, vol. 399,, no. 3, 16 December 1996, pages 232-236, XP002075140 Amsterdam, NL
AC	D. LUO ET AL.: "V1-linker-Vh orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the framework regions." JOURNAL OF BIOCHEMISTRY, vol. 118, NO. 4, 1 October 1995, pages 825-831, XP002075145 Tokyo, Japan
AD	E. MANSFIELD ET AL.: "Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies." BIOCONJUGATE CHEMISTRY, vol. 7, no. 5, September 1996, pages 557-563, XP002075147 Washington, DC, USA
AE	E. MANSFIELD ET AL.: "Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors." BLOOD, vol. 90, no. 5, 1 September 1997, pages 2020-2026, XP002075148 New York, NY, USA
AF	V. RAJAGOPAL ET AL.: "A form of anti-Tac(Fv) which is both single-chain and disulfide-stabilized for imaging CD25+ tumors." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 8, March 1997, page 27 XP002075144 USA see abstract #180
AG	M. RODRIGUES ET AL.: "Development of a humanized disulfide-stabilized anti-p185HER2 Fv-betalactamase fusion protein for activation of a cephalosporin doxorubicin prodrug." CANCER RESEARCH, vol. 55, NO. 1, 1 January 1995, pages 63-70, XP002075146 Baltimore, MD, USA
EXAMINER	DATE CONSIDERED 3/24/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.